Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information

British Journal of Haematology

Volumn 184, Issue 3, 2019, Pages 457-460

  Minetto, Paola ^a   Guolo, Fabio ^a   Clavio, Marino ^a   Kunkl, Annalisa ^a   Colombo, Nicoletta ^a   Carminati, Enrico ^a   Fugazza, Giuseppina ^a   Matarese, Simona ^a   Guardo, Daniela ^a   Ballerini, Filippo ^a   Di Grazia, Carmen ^a   Raiola, Anna M ^a   Cagnetta, Antonia ^a   Cea, Michele ^a   Miglino, Maurizio ^a   Lemoli, Roberto M ^a   Gobbi, Marco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

acute myeloid leukaemia; flow cytometry; fludarabine; fludarabine, cytarabine, idarubicin; minimal residual disease

Indexed keywords

CYTARABINE; FLUDARABINE; IDARUBICIN; PROTEIN CBFA2T1; TRANSCRIPTION FACTOR RUNX1; WT1 PROTEIN; ANTINEOPLASTIC AGENT; VIDARABINE;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MYH11 GENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RUNX1 GENE; RUNX1T1 GENE; WT1 GENE; ADOLESCENT; BLOOD; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; SURVIVAL RATE; VIDARABINE;

EID: 85040868087     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.15106     Document Type: Letter

References (9)

1. Buccisano, F., Maurillo, L., Del Principe, M.I., Del Poeta, G., Sconocchia, G., Lo-Coco, F., Arcese, W., Amadori, S. & Venditti, A. (2012) Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood, 119, 332–341.
2. Cilloni, D., Renneville, A., Hermitte, F., Hills, R.K., Daly, S., Jovanovic, J.V., Gottardi, E., Fava, M., Schnittger, S., Weiss, T., Izzo, B., Nomdedeu, J., van der Heijden, A., van der Reijden, B.A., Jansen, J.H., van der Velden, V.H., Ommen, H., Preudhomme, C., Saglio, G. & Grimwade, D. (2009) Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European Leukemia Net study. Journal of Clinical Oncology, 1, 5195–5201.
3. Delgado, J., Pereira, A., Villamor, N., López-Guillermo, A. & Rozman, C. (2014) Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica, 99, 1410–1420.
4. Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F.R., Büchner, T., Dombret, H., Ebert, B.L., Fenaux, P., Larson, R.A., Levine, R.L., Lo-Coco, F., Naoe, T., Niederwieser, D., Ossenkoppele, G.J., Sanz, M., Sierra, J., Tallman, M.S., Tien, H.F., Wei, A.H., Löwenberg, B. & Bloomfield, C.D. (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 129, 424–447.
5. Guolo, F., Minetto, P., Clavio, M., Miglino, M., Di Grazia, C., Ballerini, F., Pastori, G., Guardo, D., Colombo, N., Kunkl, A., Fugazza, G., Rebesco, B., Sessarego, M., Lemoli, R.M., Bacigalupo, A. & Gobbi, M. (2016) High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: a critical review of a 10- year, single-center experience in younger, non M3 AML patients. American Journal of Hematology, 91, 755–762.
6. Guolo, F., Minetto, P., Clavio, M., Miglino, M., Galaverna, F., Raiola, A.M., Di Grazia, C., Colombo, N., Pozzi, S., Ibatici, A., Bagnasco, S., Guardo, D., Kunkl, A., Ballerini, F., Ghiggi, C., Lemoli, R.M., Gobbi, M. & Bacigalupo, A. (2017) Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia. Haematologica, 102, e348–e351.
7. Ragon, B.K., Daver, N., Garcia-Manero, G., Ravandi, F., Cortes, J., Kadia, T., Oran, B., Ohanian, M., Ferrajoli, A., Pemmaraju, N., Kantarjian, H.M. & Borthakur, G. (2017) Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. American Journal of Hematology, 92, 845–850.
8. Terwijn, M., van Putten, W.L., Kelder, A., van der Velden, V.H., Brooimans, R.A., Pabst, T., Maertens, J., Boeckx, N., de Greef, G.E., Valk, P.J., Preijers, F.W., Huijgens, P.C., Dräger, A.M., Schanz, U., Jongen-Lavrecic, M., Biemond, B.J., Passweg, J.R., van Gelder, M., Wijermans, P., Graux, C., Bargetzi, M., Legdeur, M.C., Kuball, J., de Weerdt, O., Chalandon, Y., Hess, U., Verdonck, L.F., Gratama, J.W., Oussoren, Y.J., Scholten, W.J., Slomp, J., Snel, A.N., Vekemans, M.C., Löwenberg, B., Ossenkoppele, G.J. & Schuurhuis, G.J. (2013) High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. Journal of Clinical Oncology, 31, 3889–3897.
9. Venditti, A., Piciocchi, A., Candoni, A., Melillo, L., Calafiore, V., Cairoli, R., De Fabritiis, P., Storti, G., Salutari, P., Lanza, F., Martinelli, G., Luppi, M., Mazza, P., Falini, B., Cuneo, A., Specchia, G., Fabbiano, F., Tafuri, A., Ronci, B., Tieghi, A., Fracchiolla, N. S., Capelli, D., Foà, R., Ronco, F., La Sala, E., Fazi, P., Maurillo, L., Buccisano, F., Del Principe, M.I., Lo Coco, F., Arcese, W. & Amadori, S. (2017) Risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia: results of the AML 1310 trial of the GIMEMA group. Haematologica, 102(s2), 6–7. (abstract s111).